Clinical Trial Update: QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for QPI-1002 in preventing delayed graft function in recipients of older donor kidneys; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function

Drugs mentioned

• QPI-1002

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Delayed Graft Function | Phase 3 | Status: COMPLETED